摘要
目的探讨静脉途径应用基于核小体的表位肽防治系统性红斑狼疮(SLE)的可行性。方法以凋亡细胞诱导的SLE样症状小鼠为模型,用核小体表位肽H2B14￣28静脉途径诱导小鼠免疫耐受,观察实验小鼠自身抗体产生情况以及SLE样临床症状改善情况。结果用表位肽H2B14￣28诱导免疫耐受以后,可显著降低实验小鼠抗核抗体(ANA)、抗双链DNA(dsDNA)抗体、抗RNP抗体和抗心磷脂(ACL)抗体的产生,同时显著改善小鼠蛋白尿、白细胞低下、肾脏免疫复合物沉积程度和病理损伤程度。结论静脉途径应用核小体表位肽H2B14￣28可有效阻止实验性SLE病变的形成,基于核小体表位肽的肽疫苗的研究有可能为SLE的防治开辟一条全新的思路和途径。
Objective To investigate the effects of immune tolerance induced by peptide based on nucleosome H2B epitopes in prevention and treatment of systemic lupus erythematosus (SLE). Methods Based on a model of experimental systemic lupus erythematosus induced with syngeneic apoptotic lymphocytes to BALB/c mice, immune tolerance was induced by H2B14~28, administration intravenously with H2B Th cell epitope peptide. The effects of prevention and treatment were evaluated by changes in autoantibodies and SLE-like clinical manifestations. Results The peptide of H2B14~28 was highly effective in preventing autoantibody production of SLE (such as ANA, anti-dsDNA Abs, anti-RNP Abs and ACL Abs), and ameliorating clinical manifestations. Conclusion Tolerance to nucleosome induced by H2B14~28 peptide can significantly inhibit autoantibodies production and down-regulate clinical manifestations of SLE. So it may be a new way to treat and prevent SLE by nucleosome-based immune tolerance vaccine.
出处
《中华风湿病学杂志》
CAS
CSCD
2005年第2期65-67,i001,共4页
Chinese Journal of Rheumatology
基金
国家自然科学基金资助项目(30200258)
